Research Opportunities
- Hemotology/Oncology (cell cycle, transcription/translation, angiogenesis)
- Cardiology/Pulmonology (angiogenesis, vascular biology, tissue injury and repair, atherosclerosis)
- Infectious Diseaeses (molecular virology, native immunity)
- Metabolic Diseases (protein folding/structure)
- Neurosciences (protein folding/structure, transcription/translation)
- Orthopedics
Industry Partnerships With Avant-Garde Technologies
Prototypic of STSI’s commitment for academic-industry collaborations and partnerships, one of the programs, Scripps Genomic Medicine, has developed a significant ring of collaborations as depicted. This has provided access to avant-garde technologies, such as Navigenics ability to run the Affymetrix 6.0 platform for > 1 million SNPs for individuals with only 2 ml of saliva. The data from Navigenic’s consumer oriented program will be shared with Scripps to investigate rare genomic variants for common disease. Partnering with the start-up Prognosys, new efficient technologies for resequencing involving pooling of samples are being explored. All of the publicly traded San Diego genome science companies are fully engaged in collaborations which include Illumina, Sequenom, Nanogen, Invitrogen, and Gen-Probe. These foster sharing of technologies that STSI would otherwise not have access to catapult its academic mission. For example, Illumina has an emerging molecular diagnostics platform for validation in a clinical population, Sequenom has mass spec for methylation sites and expression QTLs for genomic variants, and Nanogen has remarkably efficient multiplex genotyping capabilities for our community risk assessment project.
